FIELD: medicine; pharmaceutics.
SUBSTANCE: group of inventions relates to pharmaceutics and medicine. Object 1 and 2 represent the use of a polypeptide or a salt thereof for preventing or treating dementia in Alzheimer's disease. Object 3 is a method of preventing or treating dementia in Alzheimer's disease, involving administering to a subject in need thereof a polypeptide or a salt thereof. Object 4 is the use of a polypeptide or its salt for preparing a drug for treating dementia in Alzheimer's disease.
EFFECT: suppression of LPS-mediated cytokine production, suppression of LPS-induced neuroinflammation, normalization of cognitive disorders, suppression of aggregation of beta-amyloid or tau-protein, suppression of neuron death, passage through blood-brain barrier by polypeptide or its salt, prevention, or treatment of dementia in Alzheimer's disease.
7 cl, 8 dwg, 8 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| POLYPEPTIDE WITH ANTIBACTERIAL ACTIVITY, COMPOSITION FOR THE PREVENTION OR TREATMENT OF SEPSIS WHICH INCLUDES IT, AND ANTIBACTERIAL COMPOSITION | 2020 |
|
RU2797347C2 |
| FUSED MOLECULE CAPABLE OF INDUCING NON-INFLAMMATORY PHAGOCYTOSIS | 2022 |
|
RU2823919C1 |
| FUSED PROTEIN CONTAINING A VERSION OF CCL3, AND USE THEREOF | 2017 |
|
RU2727715C2 |
| ANTIBODY-DRUG CONJUGATES INCLUDING ANTIBODY AGAINST HUMAN DLK1 AND THEIR USE | 2020 |
|
RU2801630C2 |
| CONJUGATE OF LONG-ACTING PHYSIOLOGICALLY ACTIVE SUBSTANCE AND ITS USE | 2018 |
|
RU2773823C2 |
| ANTIBODIES AGAINST TIGIT AND APPLICATION THEREOF | 2019 |
|
RU2750705C1 |
| IGG4 Fc FRAGMENT CONTAINING A MODIFIED HINGE REGION | 2014 |
|
RU2800558C1 |
| COMPOSITION FOR PREVENTION, RELIEF OF SYMPTOMS, OR TREATMENT OF NEURODEGENERATIVE DISEASES, CONTAINING PEDIOCOCCUS INOPINATUS | 2020 |
|
RU2791695C2 |
| ANTIBODIES AGAINST VISTA AND APPLICATION THEREOF | 2018 |
|
RU2750723C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING INSULIN AND GLUCAGON | 2019 |
|
RU2823246C2 |
